ProPhase Labs, Inc. Segment Reporting Other Item Amount
ProPhase Labs, Inc. (PRPH) reported Segment Reporting Other Item Amount of $2.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-19
- ProPhase Labs, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $2.64M, a 22.68% decline year-over-year.
- ProPhase Labs, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $3.47M, a 14.52% decline year-over-year.
- ProPhase Labs, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $8.87M, a 43.95% decline year-over-year.
- ProPhase Labs, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was $6.17M, a 0.31% increase year-over-year.
- ProPhase Labs, Inc. segment reporting other item amount for fiscal 2025 was $22.52M, a 37.43% decline from fiscal 2024.
- ProPhase Labs, Inc. segment reporting other item amount for fiscal 2024 was $35.99M, a 12.82% increase from fiscal 2023.
- ProPhase Labs, Inc. segment reporting other item amount for fiscal 2023 was $31.90M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 3 month as first filed | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.64M 10-Q · filed 2026-08-19 | $6.12M 10-Q · filed 2026-08-19 | $14.98M derived: sum of 3 quarters · filed 2026-08-19 | $21.16M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2026-03-31 | $3.47M 10-Q/A · filed 2026-07-09 | $3.52M 10-Q · filed 2026-06-30 | $12.34M derived: sum of 2 quarters · filed 2026-07-09 | $18.51M derived: sum of 3 quarters · filed 2026-07-09 | $21.93M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $15.04M derived: sum of 2 quarters · filed 2026-06-01 | $18.46M derived: sum of 3 quarters · filed 2026-08-19 | $22.52M 10-K · filed 2026-06-01 | |
| 2025-09-30 | $6.17M 10-Q · filed 2025-11-19 | $9.59M derived: sum of 2 quarters · filed 2026-08-19 | $13.65M 10-Q · filed 2025-11-19 | $29.47M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-06-30 | $3.42M 10-Q · filed 2026-08-19 | $7.48M 10-Q · filed 2026-08-19 | $23.30M derived: sum of 3 quarters · filed 2026-08-19 | $29.45M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-03-31 | $4.06M 10-Q/A · filed 2026-07-09 | $19.88M derived: sum of 2 quarters · filed 2026-07-09 | $26.04M derived: sum of 3 quarters · filed 2026-07-09 | $32.10M derived: sum of 4 quarters · filed 2026-07-09 | |
| 2024-12-31 | $15.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $21.97M derived: sum of 2 quarters · filed 2026-06-01 | $28.04M derived: sum of 3 quarters · filed 2026-06-01 | $35.99M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $6.16M 10-Q · filed 2025-11-19 | $12.22M derived: sum of 2 quarters · filed 2025-11-19 | $20.18M 10-Q · filed 2025-11-19 | ||
| 2024-06-30 | $6.06M 10-Q · filed 2025-08-13 | $12.47M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $6.42M 10-Q · filed 2025-05-20 | ||||
| 2023-12-31 | $31.90M 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |